Reports

Turquoise's Public Comment on CMS-1850-P

Turquoise's public comments to CMS on the CY 2027 OPPS/ASC proposed rule: a JSON MRF schema, bundled shoppable services, and 340B impacts by hospital type.

How AI is changing work for managed care teams

Thousands of questions from health systems, hospitals, and physician groups tell us where AI is actually making a difference in managed care’s day-to-day work

Turquoise's public comment on CMS 9882-P

Transparency in Coverage files are on the verge of a much-needed overhaul to become leaner, more organized, and more useful.

2025 price transparency impact report

Breaking down what payers are doing well, where gaps remain, and what’s changing next.

Turquoise's public comment on CMS-1834-P

Turquoise Health's public comment on CMS-1834-P supporting comprehensive hospital MRF standards, seeking clarification on new percentile fields, and providing recommendations on EDI 835 ERA transaction data utility. Read our full analysis.

2025 drug reimbursement trends report

Turquoise Health and ZS's 2025 drug reimbursement trends report analyzes millions of hospital and payer-reported drug rates across 17 products and 4 therapeutic areas revealing how payer-provider dynamics drive reimbursement from 3× to 10× ASP. Explore the data.

Turquoise's public comment on CMS hospital price transparency accuracy and completeness RFI

Turquoise Health's full response to the CMS hospital price transparency accuracy & completeness RFI defining accuracy and completeness of MRF data and recommending how CMS should enforce meaningful compliance going forward. Read our full analysis.

Turquoise's public comment on CMS-9882-NC

Turquoise Health's public comment on CMS-9882-NC supporting the expansion of price transparency to include prescription drugs and making the case for comprehensive drug rate disclosure as critical healthcare infrastructure. Read our full analysis.

Turquoise's public comment on CMS-0042-NC

Turquoise Health's public comment on CMS-0042-NC supporting binding upfront cost estimates and providing detailed feedback on PC-12 and TD-19 regarding price transparency implementation and good faith estimate frameworks. Read our full analysis.